Topical treatment of melanoma skin metastases with imiquimod;Tratamiento tópico de las metástasis cutáneas de melanoma con imiquimod

Actas Dermo-Sifiliograficas

Volumn 96, Issue 2, 2005, Pages 111-115

  Sigüenza, Mercedes ^a,b,c   Pizarro, Ángel ^a,b   Mayor, Matías ^a   Vidaurrázaga, Carmen ^a   Miralles, Lara ^a   González Beato, María ^a   Casado, Mariano ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Instituto Madrileno de Oncologia   (Spain)

^c NONE   (Spain)

Author keywords

Imiquimod; Melanoma; Skin metastases

Indexed keywords

ALPHA2B INTERFERON; IMIQUIMOD; IMMUNOMODULATING AGENT; LACTATE DEHYDROGENASE; TOLL LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; CANCER PALLIATIVE THERAPY; CASE REPORT; DRUG EFFICACY; HUMAN; MALE; MELANOMA; SCALP; SKIN METASTASIS;

EID: 17144377110     PISSN: 00017310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-7310(05)73048-9     Document Type: Article

References (16)

1. Martí RM, Puig S, Malvehy J, et al. Tratamiento del melanoma metastásico. Piel. 2003;18:216-28.
2. Steinmann A, Funk JO, Schuler G, Von den Driesch P. Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol. 2000;43:555-6.
3. Ugurel S, Wagner A, Pföhler C, Tilgen W, Reinhold U. Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread. Br J Dermatol. 2002;147:621-4.
4. Bong AB, Bonnekoh B, Franke I, Schön MP, Ulrich J, Gollnick H. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology. 2002;205:135-38.
5. Wolf IH, Smolle J, Binder B, Cerroni L, Richtig E, Kerl H. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol. 2003;139:273-6.
6. Vereecken P, Mathieu A, Laporte M, et al. Management of cutaneous locoregional recurrences of melanoma: a new therapeutic perspective with imiquimod. Dermatology. 2003;206:279-80.
7. Hesling C, D'Incan M, Mansard S, et al. In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases. Br J Dermatol. 2004;150:761-7.
8. Rhodes J. Discovery of immunopotentiatory drugs: current and future strategies. Clin Exp Immunol. 2002;130:363-9.
9. Akira S. Mammalian Toll-like receptors. Curr Op Immunol. 2003;15:5-11.
10. Schön M, Bong AB, Drewniok C, et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst. 2003;95:1138-49.
11. Stockfleth E, Meyer T, Benninghoff B, Christofers E. Successful treatment of actinic keratoses with imiquimod cream 5%: a report of six cases. Br J Dermatol. 2001;144:1050-3.
12. Mackenzie-Wood A, Kossard S, de Launey J, Wilkinson B, Owens ML. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol. 2001;44:462-70.
13. Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol. 2001;44:807-13.
14. Ahmed I, Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol. 2000;143:843-5.
15. Martínez MI, Sánchez-Carpintero I, North PE, Mihm MC. Infantile hemangioma: clinical resolution with 5% imiquimod cream. Arch Dermatol. 2002;138:881-4.
16. Suzuki H, Wang B, Shivji GM, et al. Imiquimod, a topical immune reponse modifier, induces migration of Langerhans cells. J Invest Dermatol. 2000;114:135-41.